Storys aus Lausanne

Schweizerischer Nationalfonds / Fonds national suisse

SNSF image competition 2019: Participate and share unexpected insights into science

Bern (ots) - Following the success of the first two editions, the Swiss National Science Foundation has decided to stage its competition for images and short videos from the world of science for a third time. The best entries will be showcased in various exhibitions and via social media. The over 800 entries in 2017 and 2018, and the enthusiasm generated among the ...

Schweizerischer Nationalfonds / Fonds national suisse

Latsis Prize 2018: Andrea Ablasser unlocks the secret of rapid virus defence

Tetra Pak GmbH & Co KG

Tetra Pak Achieves 50% Renewable Electricity Consumption in Just Two Years Since RE100 Commitment

Lausanne, Switzerland (ots/PRNewswire) - Tetra Pak now obtains half of its global electricity supply from renewable sources, putting the company firmly on course to meet its RE100 commitment of using only renewable electricity across all global operations by 2030. (Logo: https://mma.prnewswire.com/media/632361/Tetra_Pak_Logo.jpg ) (Photo: ...

Tetra Pak GmbH & Co KG

Tetra Pak Index 2018 Says Smart Packaging Offers Exciting Opportunities in Fast Growing Online Grocery

Lausanne, Switzerland (ots/PRNewswire) - Smart packaging technologies based on unique digital codes will take both online and off-line grocery in exciting new directions during the next few years, says the Tetra Pak Index 2018, launched today. (Logo: https://mma.prnewswire.com/media/632361/Tetra_Pak_Logo.jpg ) ...

Galderma

Galderma Global Study Reveals True Burden of Rosacea and Encourages Healthcare Professionals to Look 'Beyond the visible'

Lausanne, Switzerland (ots/PRNewswire) - Galderma today released the findings of a global survey highlighting the need for dermatologists and doctors to proactively open a dialogue with patients about the true burden of rosacea and ways in which they can work together to achieve 'clear' (IGA 0) skin*. In the form of ...

IMD

The US overtakes Hong Kong at first place among world's most competitive economies

Debiopharm International SA

Debiopharm continues the fight against antibiotic resistance with investment in ABAC Therapeutics Inc. / ABAC develops new targeted antibiotics for patients with severe infections

Lausanne (ots) - Debiopharm Group (TM) announces an investment in antibiotic development with the acquisition of a minority stake in ABAC Therapeutics Inc. This investment was made through the Debiopharm Innovation Fund, its strategic investment fund, and illustrates the synergy between the group companies in the ...

Debiopharm International SA

Debiopharm International SA Launches Clinical Trials Website: patients.debiopharm.com

Debiopharm International SA

EMA grants Orphan Drug Designation to Debiopharm International SA's FGFR inhibitor Debio 1347 in the treatment of biliary tract cancer

Lausanne (ots) - Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced that the European Medicines Agency (EMA) granted Orphan Drug Designation to Debio 1347 for treatment of Biliary Tract Cancer affecting around ...

Debiopharm International SA

Debiopharm International SA Announces Dosing of First Patient in a Combination Trial of Debio 1143 and Avelumab in Patients with Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)

Lausanne, Switzerland (ots) - The clinical trial is in collaboration with the Merck-Pfizer Alliance Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced the dosing of the first patient in a Phase Ib study of Debio ...

Debiopharm International SA

Arbor Pharmaceuticals, LLC and Debiopharm International SA Announce Commercial Availability of Triptodur(TM), Triptorelin 6-month Formulation, for Treatment of Central Precocious Puberty (CPP)

Atlanta, GA, USA and Lausanne, Switzerland (ots) - Triptodur(TM), (triptorelin) extended release injectable suspension, has been shown to arrest or reverse the clinical signs of puberty associated with CPP via a once every six-month intramuscular (IM) injection. Arbor Pharmaceuticals, LLC, a U.S. based specialty ...

Debiopharm International SA

The Japanese Cancer Association and Debiopharm Group Announce Winners of the 2017 JCA-Mauvernay Award

Lausanne (ots) - The 'JCA-Mauvernay Award 2017' is awarded to Doctors Yasuhiro Yamada and Hiroyoshi Nishikawa Debiopharm Group(TM) (Debiopharm - www.debiopharm.com), a Swiss-based global biopharmaceutical company, will be presenting the 'JCA-Mauvernay Award' on September 30 to Doctors Yasuhiro Yamada from the ...

Galderma

Galderma: 'Clear' (IGA 0) Rosacea Patients Experience a Delayed Time to Relapse

Lausanne, Switzerland (ots/PRNewswire) - Today, the results of a pooled analysis of four Galderma-sponsored studies evaluating the use of topical therapies for the treatment of inflammatory papules and pustules of rosacea were presented at the 26th European Academy of Dermatology and Venereology Congress in Geneva, Switzerland. The success of rosacea treatment is ...

Galderma

Galderma: Combined Use of Rosacea Therapies Ivermectin 1% Cream and Brimonidine 0.33% Gel Evaluated in MOSAIC Study

Lausanne, Switzerland (ots/PRNewswire) - Today, the results of a study evaluating the combined use of topical rosacea treatments ivermectin 1% cream and brimonidine 0.33% gel were published in the Journal of Drugs in Dermatology. (Logo: http://mma.prnewswire.com/media/554005/Galderma_Logo.jpg ) "This is the first ...

Debiopharm International SA

Debiopharm International SA Awarded $2.6 Million Grant from CARB-X to Support Development of Debio 1453 to fight drug resistant gonorrhea

Lausanne (ots) - Debiopharm, in collaboration with CARB-X, will utilize their state-of-the-art Fabiotics platform to develop novel therapeutics to combat drug-resistant gonorrhea. Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical ...

Debiopharm International SA

Debiopharm International SA and Arbor Pharmaceuticals, LLC Announce U.S. FDA Approval for Triptodur(TM), Triptorelin 6-month Formulation, in the Treatment of Central Precocious Puberty (CPP)

Lausanne, Switzerland and Atlanta, GA (ots) - Triptodur (TM), (triptorelin) for extended release injectable suspension, has been shown to arrest or reverse the clinical signs of puberty with once every six-month intramuscular injection (IM) dosing for children with CPP Approval brings new CPP treatment formulation ...

Debiopharm International SA

Almac Discovery and Debiopharm International SA Announce a Licensing Agreement for the Development of a Novel Wee-1 Inhibitor

Craigavon, N.I., UK, Lausanne, Switzerland (ots) - Almac Discovery (www.almacgroup.com/discovery), a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, and Debiopharm International SA (Debiopharm - www.debiopharm.com), a Switzerland based specialty ...

Debiopharm International SA

Debiopharm International SA Announces Completion of Enrollment in Phase I/II Clinical Trial with Debio 1143 in SCCHN

Lausanne (ots) - A total of 96 patients randomized in France and Switzerland. Results expected in Q1 2019. Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced the completion of enrollment in dose finding and ...

Debiopharm International SA

GenePOC announces FDA clearance for revogene(TM) instrument and its GBS LB test

Québec, Canada and Lausanne, Switzerland (ots) - GenePOC announces it received 510(k) clearance from the US Food and Drug Administration to market its first molecular assay to detect Group B Streptococcus and for the revogene molecular diagnostics instrument. GenePOC, Inc. (GenePOC) a member of the Debiopharm Group is pleased to announce that it has received FDA ...

Debiopharm International SA

Debiopharm International SA Announces Results from Phase I Dose-Escalation Study of Debio 1347/CH5183284

Lausanne, Switzerland (ots) - Debio 1347/CH5183284 was evaluated in patients with FGFR genomically activated advanced solid tumors Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced the results from the phase I ...

Debiopharm International SA

Debiopharm International SA Enters the Field of Antibody-Drug Conjugates Through Acquisition of Phase II Asset from ImmunoGen

Lausanne, Switzerland and Waltham, Mass. (ots) - Transaction adds innovative clinical-stage program to expanding Debiopharm portfolio and broadens its clinical development expertise Divestiture aligns with ImmunoGen's focus on strategic growth initiatives and generates near-term value Debiopharm International SA ...

Debiopharm International SA

BC Platforms Closes USD $10 million Series B Financing led by Debiopharm and Tesi to accelerate knowledge platform development

Basel, Switzerland, Lausanne, Switzerland and Helsinki, Finland (ots) - Leading Big Data company developing platform with clinical and genomic data from 5 million subjects, to transform drug development and bring clinical benefits to patients. BC Platforms, a world leader in genomic data management solutions, today ...

Debiopharm International SA

Debiopharm Innovation Fund: the New Name and Investment Strategy of Debiopharm Diagnostics

Lausanne (ots) - Change in name reflects new strategy to invest in smart data, therapeutics and diagnostics Debiopharm Diagnostics SA, the strategic investment fund of Debiopharm Group(TM) (www.debiopharm.com), announced its new strategy and the change of name to Debiopharm Innovation Fund SA effective today. With the aim of speeding up innovations that radically ...

Debiopharm International SA

GenePOC announces product launch in Europe and Middle East

Québec, Canada/Lausanne, Switzerland (ots) - GenePOC announces the commercialization of its Clostridium difficile and Group B Strep molecular tests in Europe, along with onboarding additional partners to cover the EMEA market GenePOC, Inc. (GenePOC) a member of the Debiopharm Group is proud to announce that it has started the commercialization of its first two CE-IVD marked tests, GenePOC(TM) CDiff and GenePOC(TM) GBS ...

Debiopharm International SA

Debiopharm International SA Initiates Clinical Phase II Study Evaluating Debio 1143 in Ovarian Cancer

Lausanne, Switzerland (ots/PRNewswire) - Debiopharm today announced the start of a phase II clinical trial for Debio 1143 in combination with standard of care Carboplatin and Paclitaxel in Epithelial Ovarian Cancer Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global ...

Debiopharm International SA

FDA Grants Orphan Drug Designation to Debiopharm International SA's IAP Inhibitor Debio 1143 in the Treatment of Ovarian Cancer

Lausanne, Switzerland (ots/PRNewswire) - Debiopharm International SA (Debiopharm), a Swiss-based company, part of Debiopharm Group(TM), today announced that the FDA Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation to Debio 1143 for treatment of ovarian cancer. Orphan Drug Designation ...

Debiopharm International SA

Debiopharm International SA Announces Presentation at AACR of Non-clinical Data Relating to its Targeted Investigational Compound Debio 1347/CH5183284, a Selective FGFR 1,2,3 Inhibitor

Lausanne, Switzerland (ots/PRNewswire) - Debiopharm International SA (Debiopharm), a Swiss-based company, part of Debiopharm Group(TM), today announces that non-clinical data on the clinical-stage investigational compound Debio 1347/CH5183284 (FGFR 1,2,3 inhibitor) will be presented at the 2016 Annual Meeting of the ...

Debiopharm International SA

Debiopharm International SA to Present the Latest Findings on Debio 1450 at ECCMID

Lausanne, Switzerland (ots/PRNewswire) - Debiopharm will be present at ECCMID in Amsterdam to share new data supporting the clinical development of its first in class Staphylococcus-selective antibiotic Debio 1450 Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced three communications ...

zip.ch SA

Zip.ch raises CHF 1.5 million to speed up its expansion

Debiopharm International SA

Debiopharm International SA Has Won Its Patent Infringement Suit for Elplat® Against Nippon Kayaku Co., Ltd.

Lausanne, Switzerland (ots/PRNewswire) - Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company today announces that the Tokyo District Court granted Debiopharm an overall victory for the first instance demanding the suspension of patent infringement of ...